<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0340">
 <label>68</label>
 <element-citation publication-type="journal" id="sbref0340">
  <person-group person-group-type="author">
   <name>
    <surname>Jiaming</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Yanfeng</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Yao</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Yawei</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Linlin</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Baoying</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Jinghua</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Gao</surname>
    <given-names>G.F.</given-names>
   </name>
   <name>
    <surname>Chuan</surname>
    <given-names>Q.</given-names>
   </name>
   <name>
    <surname>Wenjie</surname>
    <given-names>T.</given-names>
   </name>
  </person-group>
  <article-title>The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection</article-title>
  <source>Vaccine</source>
  <volume>35</volume>
  <year>2017</year>
  <fpage>10</fpage>
  <lpage>18</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.064</pub-id>
  <pub-id pub-id-type="pmid">27899228</pub-id>
 </element-citation>
</ref>
